Acne vulgaris may occur as part of immune reconstitution in human immunodeficiency virus (HIV)-seropositive patients on highly active antiretroviral therapy (HAART). Tetracyclines are a common acne treatment. Hypertriglyceridemia has not been reported as a side effect of this drug class.
Objective:
We report a case of an HIV-seropositive man on HAART (CD4 count 450 cells/μL) who developed isolated hypertriglyceridemia (> 13 mmol/L) after three separate challenges with minocycline or tetracycline, improving each time therapy was discontinued.
Results:
Based on a review of the literature, this is the first reported case of hypertriglyceridemia with minocycline or tetracycline therapy. No published reports have examined the safety of tetracyclines in the setting of HIV or HAART.
Conclusion:
A strong temporal association between tetracycline use and hypertriglyceridemia was found without an alternate explanation for the observed lipid profile. Given the common use of tetracyclines in dermatology, we feel that this is an important observation to report.
Get full access to this article
View all access options for this article.
References
1.
KreuterASchlottmannRAltmeyerPBrockmeyerNH. Acne vulgaris as an immune reconstitution syndrome in a patient with AIDS after initiation of antiretroviral therapy. J Eur Acad Dermatol Venereol2002;16:638.
2.
GallinJIKayeDO'LearyWM. Serum lipids in infection. N Engl J Med1969;281:1081–6.
3.
SammalkorpiKValtonenVKerttulaY. Changes in serum lipoprotein pattern induced by acute infections. Metabolism1988;37:859–65.
4.
GrunfeldCPangMDoerrlerW. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab1992;74:1045–52.
5.
GrunfeldCKotlerDPShigenagaJK. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med1991;90:154–62.
6.
GreenML. Evaluation and management of dyslipidemia in patients with HIV infection. J Gen Intern Med2002;17:797–810.
7.
MarkowitzMSaagMPowderlyWG. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med1995;333:1534–9.
8.
MartinezEGatellJ. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet1998;352:821–2.
9.
MillerKDJonesEYanovskiJA. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet1998;351:871–5.
10.
SullivanAKNelsonMR. Marked hyperlipidaemia on ritonavir therapy. AIDS1997;11:938–9.
11.
WalliRHerfortOMichlGM. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS1998;12:F167–73.
12.
GrinspoonSCarrA. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med2005;352:48–62.
13.
TershakovecAMFrankIRaderD. HIV-related lipodystrophy and related factors. Atherosclerosis2004;174:1–10.
14.
CarrASamarasKChisholmDJ. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet1998;351:1881–3.
15.
CarrASamarasKBurtonS. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS1998;12:F51–8.
16.
CarrASamarasKThorisdottirA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet1999;353:2093–9.
17.
MadgeSKinloch-de-LoesSMerceyD. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS1999;13:735–7.
18.
ThiebautRDabisFMalvyD. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). J Acquir Immune Defic Syndr2000;23:261–5.
19.
SavesMRaffiFCapeauJ. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis2002;34:1396–405.
20.
Saint-MarcTPartisaniMPoizot-MartinI. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS1999;13:1659–67.
21.
BrinkmanKSmeitinkJARomijnJA. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet1999;354:1112–5.
22.
BrinkmanKter HofstedeHJBurgerDM. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS1998;12:1735–44.
23.
MartinezECongetILozanoL. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS1999;13:805–10.
24.
ScheweCKMaseratiRWassmerG. Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment. Clin Infect Dis2006;42:145–7.
25.
ViganoAAldrovandiGMGiacometV. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther2005;10:917–24.
